Who is sponsoring NCT03977831?

NCT03977831 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03977831?

Interventions in NCT03977831: Radical Cystectomy.

What condition does NCT03977831 study?

NCT03977831 studies Urinary Bladder Neoplasms.

Is NCT03977831 still recruiting?

NCT03977831 is currently completed. Last updated 26 January 2021.

Last reviewed 2021-01-26 · How we verify

NCT03977831

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer

Completed NA Last updated 26 January 2021

What this trial tests

NA trial testing Radical Cystectomy in Urinary Bladder Neoplasms in 50 participants. Completed in 20 January 2021.

Timeline

6 June 2019

Primary endpoint
1 November 2020

20 January 2021

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	6 June 2019
Primary completion	1 November 2020
Estimated completion	20 January 2021
Sites	1 location across Denmark

Drugs / interventions tested

Radical Cystectomy

Conditions studied

Urinary Bladder Neoplasms — all drugs for Urinary Bladder Neoplasms →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Urinary Bladder Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study to compare two established methods of radical cystectomy (RC) in patients with bladder cancer. The participants will be treated under conditions in alignment with up-to-date guidelines and care. We wish to investigate whether it is feasible to compare the two methods under conditions of the highest methodological quality.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Robot-assisted laparoscopic radical cystectomy with intracorporeal ileal conduit diversion versus open radical cystectomy with ileal conduit for bladder cancer in an ERAS setup (BORARC): protocol for a single-centre, double-blinded, randomised feasibility study.
Maibom SL, Joensen UN, Aasvang EK, Rohrsted M, et al · · 2023 · cited 2× · PMID 36639814 · DOI 10.1186/s40814-022-01229-3

Verify or expand the search:

Other trials of Radical Cystectomy

Trials testing the same drug.

NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07202819 — Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy · NA · recruiting
NCT06263153 — Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patie · Phase 2 · recruiting
NCT06091124 — Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma · Phase 2 · recruiting
NCT05581589 — Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer · Phase 2 · recruiting

Other recruiting trials for Urinary Bladder Neoplasms

Currently open trials in the same condition.

NCT07222488 — A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) · Phase 1, PHASE2 · recruiting
NCT06421142 — FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer · NA · active not recruiting
NCT04369560 — Virtual Histology of the Bladder Wall for Bladder Cancer Staging · EARLY_PHASE1 · recruiting
NCT06960577 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cance · Phase 3 · recruiting
NCT06833073 — A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · Phase 2 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03977831 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 26 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03977831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing